<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 359 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page358.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=359">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 359 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 359</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=359"><img src="../thumb/359.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>322 / 2020-04                                                                 Cytostatics - 23
   doxorubicin for loc. advanc.or metastat.breast Ca in pts.who have   Indications: Breast Ca incl.loc.advanc./metastat. dis., non-Hodgkin’s   NEXAVAR 200, Bayer [P/S]
   not prev.receiv.cytotox.ther.for this condit., as monother. for loc.ad-  lymphoma, adult ac.non-lymphocyt. leukaem.at relapse and chron.   Sorafenib
   vanc.or metastat.breast Ca aft. fail.of cytotox.ther., in combin.with   myelogen. leukaem.in blast crisis, combin.with low dos.oral corti-  Indications: Advanc.renal cell Ca, advanc. inoperable hepatocell.
   capecitabine for loc.advanc.or metastat.breast Ca aft.fail.of cytotox.   coster.as init.chemother.for symptomat. treatm.of intract.pain,relat.  Ca, loc.advanc./metast. different.thyroid Ca refract.to radioact.Iodine
   ther.where prev.ther.should have incl.an anthracycline., in combinat.  to advanc. hormone-refract.prostate Ca.  (S4) TABS, A40/26/0776
   with cisplatin for unresect. loc.advanc./metastat.non-small cell lung   (S4) SOL FOR INFUS, 37/26/0168  708482-002: 200 mg, 60, R13 876,49
   Ca when chemother.not prev.admin., loc.advanc./ metast. non-small   708724-001, 20 mg/10 ml, glass vial, R3 189,74  For further details see manufact.prod.lit.
   cell lung Ca even aft.fail.of platinum-bas. chemother., metastat.ovar.  For further details refer to manufacturer’s lit.
   Ca.aft. fail. of 1st line /subseq.chemother., in combin.with prednisone/   ONCOGEM, Cipla Medpro [P/S]
   prednisolone for horm.refract. metastat. prostate Ca, in combin.with   MIVESTA, (Eurolab) Accord [P/S]  Gemcitabine.
   cisplatin & 5-fluorouracil for induct.treatm.of pts.with inoper. loc. ad-  Imatinib  Indications: Loc.advanc./metastat.non-small cell lung Ca, 1st line
   vanc.squamous cell Ca of the head & neck.  Indications: Adults & paed.pts: New.diagn Philadelph. chromo-  treatm.in loc.advanc.non-resect. stage II & III or metast.stage IV
   (S4) CONC.FOR SOL FOR INFUS. 5/26/0328, 0329. 40 mg/ml.  some posit.chron.myeloid leukaem (CML)., CML in blast crisis/ac-  adenocarcinoma of pancreas, pts.prev.treat.with 5-FU for adeno-
   723793-001: 20 mg, 1x2 ml, R756,58  celerat./ chron. phase aft.interferon-alpha ther.fail.  carcinoma of pancreas, transit.cell bladd. Ca, unresect./loc.recurr./
   723794-001: 80 mg, 1x8 ml, R3 026,32.  Adults: New.diagn Philadelph.chromosome posit. ac.lymphoblast.  metastat.breast Ca in combin.with paclitaxel in pts.who have relaps.
   For further details refer to manufact.prod.lit.  leukaem.(Ph + ALL) integrat.with chemother., monother.in relaps./  follow.adjuv./neo-adjuv.ther.where prior chemother. should have incl.
                                refract.Ph+ All, myelodysplast./myeloproliferat.dis.assoc.with platel.-  an anthracycl.unless C/I, alone/in combinat.for recurr.epithel.ovar.
   LANVIS, (Aspen Pharmacare: Pharma) Pharmacare [P/S]  deriv.growth fact.recept.gene re-arrangem., system.mastocytos.with-  Ca relaps.follow.platin.bas.chemother.
   Thioguanine.                 out D816V c-kit mutat.& eosinophil., hypereosinophilic syndr.&/or   (S4) POWD.FOR INJ. 43/26/1171, 1172.
   Indications: Ac.myelocyt.leukaem., chron. myelocyt. leukaem.in   chron. eosinophil.leukaem.wih FIP1L1-PDGFR alpha re-arrangem.,   718303-001: 200 mg, sngl.vials, R303,09
   combinat.with other.ther.    unresect.&/or metastat.malign. gastrointest. stromal tumours   718304-001: 1 000 mg, sngl.vials, R1 515,45
   (S4) TABS. C/26/119.         (GIST), unresect, recurr. &/or metastat.dermafibrosarcoma protuber.  For furth.details refer to manufact.product lit.
   735825-009: 40 mg, 25, R2 589,99  (S4) TABS, 49/26/0742, 0743
   For further details refer to manufact.prod.lit.  722940-001: 100 mg, 60, R6 050,76  OPLAXIN, Accord [P/S]
                                                              Oxaliplatin
   LARACIT, (Cipla Medpro) Teva [P/S]  722964-001: 400 mg, 30, R11 003,50  Indications: In combinat.with 5-fluorouracil & folinic acid for meta-
                                For further details refer to manufact.prod.lit.
   Cytarabine.                                                stat.colorect.Ca and adjuv. treatm.of colon Ca.
   Indications:.Adults & childr.with ac.lymphocyt./ non-lymphocyt.leu-  MYLAN IRINOTECAN, (Mylan) Xixia [P/S]  (S4) CONC.FOR SOL.FOR.INFUS., 46/26/0212, 0213
   kaem., blast cris.in CML, Non-Hodgkin’s lymphoma of high malign.  Irinotecan HCl trihydrate.  723389-001: 50 mg, 1x10 ml vial, R890,10
   in combin. with other agents, high risk leukaem.(eg.ac. leukaem.as   Indications: Advanc.colorect.Ca with WHO perform.status of 2 or   723390-001: 100 mg, 1x20 ml vial, R1 780,20
   second.malign.aft.preced.chemother. and/or radiat.and transformat.  low., in combinat.with 5-fluorouracil and folinic acid without prior   For further details refer to manufact.product lit.
   of preleukaem.), refract.ac.lymphocyte/non-lymphocyte leukaem.  chemother. for advanc.dis., as sngl.agent when est. 5-fluorouracil
   (S4) INJ. 37/26/0488. 100 mg/2 ml.  contain.regim.has fail.  OXALIPLATIN KEY, Key Oncologics [P/S]
   708730-001: 500 mg vial, 1, R166,16  (S4) SOL.FOR INFUS. 43/26/0349, 0348. 20 mg/ml.  Oxaliplatin
   For further details refer to manufact.prod.lit.  717026-001: 40 mg/2 ml, sngl.dos.vial, R405,54  Indications: In combinat.with 5-fluorouracil & folinic acid for met-
                                                              astat.colorect.Ca and adjuv. treatm. of colon Ca.
   LASPAR, (Aspen Pharmacare: Pharma) Pharmacare [P/S]  717027-001: 100 mg/5 ml, sngl.dos.vial, R1 013,84 For further info.  (S4) POWD.FOR INJ. 45/26/0330, 0331.
   L-asparaginase (amidohydrolase).  refer to manuf.product lit.  723795-001: 50 mg, 1x10 ml, R1 059,21
   Indications: Lymphoblast.leukaem.  MYLAN PACLITAXEL, (Mylan) Xixia [P/S]  723796-001: 100 mg, 1x20 ml, R2 118,42
   (S4) POWD.FOR INJ. C/26/163.  Paclitaxel.                  For further details refer to manufact.prod.lit.
   736031-006: 10 000 iu, single vials, R1 327,31  Indications: Palliat.treatm.of stage 3/4 advanc. loc. ovar.Ca aft.surg.
   For further details refer to manufact.lit.  resect.in combinat.with cisplatin, palliat.managem.of metastat.ovar.  OXALIPLATIN PCH, (Cipla Medpro) Teva [P/S]
                                                              Oxaliplatin
   LEUKERAN, (Aspen Pharmacare: Pharma) Pharmacare [P/S]  Ca aft. fail.of first line/subseq.chemother., metastat. breast Ca aft.  Indications: In combinat.with 5-fluorouracil & folinic acid for meta-
   Chlorambucil.                combinat.chemother.fail./relapse within 6 mnths of adjuvant chem-  stat.colorect.Ca and adjuv. treatm. of colon Ca.
   Indications: Hodgkin’s dis., cert.forms of non-Hodgkin’s lymphoma,   other.(prev. chemother. should have incl.an anthracycline unless   (S4) CONC.FOR SOL.FOR INFUS., 43/26/0102, 0103. 5 mg/ml
   chron.lymphocytic leukaem., Waldenstran’s macroglobulinaemia  clinic.C/I), palliat.treatm.of advanc.non-small cell lung Ca when cu-  717567-001, 50 mg/10 ml, 1 vial, R890,09
   (S4) TABS. H2747.            rat.surg.and/or radiat. not applic.  717569-001, 100 mg/20 ml, 1 vial, R1 780,18
   737887-001: 2 mg, 25, R467,14  (S4) CONC.FOR DILUT FOR INFUS. 42/26/0657; 0658; 0659.   For further details refer to manufact.prod.lit.
   For further details refer to manufact.prod.lit.  6 mg/ml   OXALIWIN, Winthrop [P/S]
                                716908-001: 30 mg/5 ml, 1 vial, R131,75
   LITAK 10, Key Oncologics P/S]  716909-001: 100 mg/16,7 ml, 1 vial, R440,10  Oxaliplatin
   Cladribine                   716910-001: 300 mg/50 ml, 1 vial, R1 317,64  Indications: Metastat.colorect.Ca & adjuv.colon Ca treatm.in com-
   Indications:Hairy cell leukem.  For further details refer to manufact.prod.lit.  binat.with 5-fluorouracil & folinic acid
   (S4) INJ.38/26/0057. 10 mg/5ml.                            (S4) RTU SOL FOR INFUS, A39/26/0521, 0522
   710351-001: 1x10 mg sngl.vial, R5 891,43  MYLERAN, (Aspen Pharmacare: Pharma) Pharmacare [P/S]  710319-001: 50 mg/10 ml, 1 vial, R886,75
   For further details refer to manufact.prod.lit.  Busulphan.  710317-001: 100 mg/20 ml, 1 vial, R1 772,90
                                Indications: Chron.granuloc.leukaem.
   MEKINIST, Novartis [P/S]     (S4) TABS. H2750.             For further details refer to manufact. product lit.
   Trametinib                   745413-005: 2 mg, 100, R1 350,17  P&U CARBOPLATIN, Pfizer [P/S]
   Indications: Unresectable/metastat.melanoma with BRAF V600 mu-  For further details refer to manufact.prod.lit.  Carboplatin.
   tat.in combinat.with dabrafenib, advanc.non-small cell adenocarcin.   Indications: Advanc.ovarian & small cell lung Ca
   with BRAF V600 mutat.in combinat.with dabrafenib  NAVELBINE, Pierre Fabre [P/S]  (S4) CSV INJ. 29/26/0501, 30/26/0310.
   (S4) TABS, 51/32.2/0819, 0820   Vinorelbine tartr.         840866-003: 10 mg/ml, 1x15 ml vials, R428,21
   3000962-001: 0,5 mg, 30, R6 077,75  Indications: Palliat.treatm.of advanc.inoper. non-small cell lung Ca   840874-006: 10 mg/ml, 1x45 ml vials, R1 284,68
   3000629-001: 2 mg, 30, R24 311,00  as a sngl.agent or in combinat. Combinat.ther.proves more effect.  For further details refer to manufac.prod.lit.
   For further details refer to prod.info.  than monother. Metastat.breast Ca in pts.where anthracycline 1 st    P&U CISPLATIN, Pfizer [P/S]
   METHACOR, Accord [P/S]       line monother.has fail.or who have relaps.with.6 mnths.of anthracy-  Cisplatin.
                                cline-based adjuv.therapy.
   Methotrexate.                (S4) INJ. 30/26/0123, 0124. 10 mg/ml.  Indications: Advanc.non seminomat.testicul tumours, pref.with
   Indications: Gen.oncology, leukaem.in childr., sev.psorias., react.  822655-004: 10x1 ml sngl.dos vial, R2 289,27  bleomycin & vinblastine, ovarian Ca partic.with doxyrubicin or cy-
   prevent.result.from bone marr. transpl., dermatomyosit., rheum.ar-  819263-001: 10x5 ml sngl.dos, R10 855,08  clophosphamide, Ca of bladder, head, neck & endometrium, small
   thrit., Wegener’s granulomatos., pityrias.rubra pilar.  (S4) ORAL CAPS, 36/26/0012, 0013  cell lung Ca, lymphomas, childhood neoplasms.
   (S4) INJ. 41/26/0305.        700191-001: 20 mg. 1, R968,19  (S4) CSV INJ. 30/26/0328, 0329.
   711328-001: 25 mg/ml, 1 ml vial, R30,43  700192-001: 30 mg, 1, R1 448,22  840858-020: 10 mg/10 ml, 1x10 ml vial, R33,26
   For further details refer to manufact.prod.lit.  For further details refer to manufact.prod.lit.  840831-005: 50 mg/50 ml, 1x50 ml vial, R166,30
   METHOTREXATE-LEDERLE, (Pfizer) [P/S]                       For further details refer to manufact.prod.lit.
   Methotrexate.                                              P&U ETOPOSIDE, Pfizer [P/S]
   Indications: Anti-neoplast.& psorias chemother., rheumatoid arthrit.  Etoposide.
   not adeq.respond.to other therapy.                         Indications: Testicul.tumours in combinat.with bleomyc.& cisplat.,
   (S4) TABS, [P/S] H2766.            Mono amine oxidase      in combinat.with cisplatin small cell lung Ca, also non-Hodgkins
   742465-004: 2,5 mg, 100, R215,50   inhibitors (MAOI) have   lymph., ac.non lymphocyt.leukaem., breast Ca, Kaposi’s sarcoma
   For further details refer to manuf.product lit.            assoc.with AIDS.
   METVIX, Galderma Laboratories SA (Pty) Ltd  a prolonged action,   (S4) CSV INJ. 30/26/0410. 100 mg/5 ml.
   See Section 14.9                   so patients should not   841021-015: 10x5 ml, R2 761,63
                                                              For further details refer to manufact.prod.lit.
   MIBLEX, Eurolab [P/S]              take any of the foods
   Bortezomib                                                 PCH PACLITAXEL, (Cipla Medpro) Teva [P/S]
   Indications: Prim.treatm.of multip.myeloma in combinat. with mel-  or medicines known   Paclitaxel.
   phalan & prednisone, monother. for multiple myeloma where at least   Indications: Palliat.treatm.of stage 3/4 advanc. loc.ovar.Ca aft.
   one prior ther.receiv.& dis.progress.  to cause reactions for   surg.resect.in combinat.with cisplatin, palliat.managem.of metastat.
   (S4) LYOPHIL.POWD.FOR SOL.FOR INJ, 50/26/0093.             ovar.Ca aft.fail.of first line/subseq.chemother., metastat. breast Ca
   1 mg/ml IVI reconstit.or 2,5 mg/ml SC reconstit  at least 14 days after   aft.combinat.chemother.fail./relapse within 6 mnths of adjuvant
   3000409-001: 3,5 mg/vial, 1x10 ml, R4 939,25               chemother.(prev. chemother.should have incl.an anthracycline un-
   For further details refer to prof.info.  stopping treatment.  less clinic.C/I), palliat.treatm.of advanc.non-small cell lung Ca when
                                                              curat.surg.and/or radiat. not applic.
   MITOXANTRONE-HEXAL, Sandoz [P/S]                           (S4) CONC.SOL.FOR INFUS. A40/26/0609, 0610, 0611. 6 mg/ml.
   Mitoxantrone HCl                                           714756-001: 30 mg, 1x5 ml vial, R130,45</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page358.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page354.html">354</a>&nbsp;&nbsp;&nbsp;<a href="page355.html">355</a>&nbsp;&nbsp;&nbsp;<a href="page356.html">356</a>&nbsp;&nbsp;&nbsp;<a href="page357.html">357</a>&nbsp;&nbsp;&nbsp;<a href="page358.html">358</a>&nbsp;&nbsp;&nbsp;<a href="page359.html">359</a>&nbsp;&nbsp;&nbsp;<a href="page360.html">360</a>&nbsp;&nbsp;&nbsp;<a href="page361.html">361</a>&nbsp;&nbsp;&nbsp;<a href="page362.html">362</a>&nbsp;&nbsp;&nbsp;<a href="page363.html">363</a>&nbsp;&nbsp;&nbsp;<a href="page364.html">364</a>
             </td>
             <td width="35%"><a href="page360.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page360.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
